S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:NTLA

Intellia Therapeutics Stock Forecast, Price & News

$60.46
+2.99 (+5.20 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$56.51
Now: $60.46
$63.00
50-Day Range
$57.47
MA: $71.12
$83.68
52-Week Range
$9.18
Now: $60.46
$92.00
Volume2.38 million shs
Average Volume1.75 million shs
Market Capitalization$3.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200
Employees270
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 million
Book Value$5.52 per share

Profitability

Net Income$-99,530,000.00
Net Margins-193.01%

Miscellaneous

Market Cap$3.57 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

669th out of 1,962 stocks

Diagnostic Substances Industry

11th out of 32 stocks

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$60.46
+2.99 (+5.20 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Intellia Therapeutics?

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Intellia Therapeutics
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its earnings results on Thursday, February, 25th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.12. Intellia Therapeutics had a negative net margin of 193.01% and a negative trailing twelve-month return on equity of 40.14%.
View Intellia Therapeutics' earnings history
.

How has Intellia Therapeutics' stock been impacted by COVID-19?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 375.3% and is now trading at $60.46.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NTLA?

14 analysts have issued 1 year target prices for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $106.00. On average, they anticipate Intellia Therapeutics' stock price to reach $54.67 in the next year. This suggests that the stock has a possible downside of 9.6%.
View analysts' price targets for Intellia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 64, Pay $903.79k)
  • Mr. Glenn G. Goddard, Exec. VP & CFO (Age 50, Pay $541.84k)
  • Dr. Andrew D. Schiermeier, Exec. VP & COO (Age 51, Pay $615.98k)
  • Dr. Laura Sepp-Lorenzino, Exec. VP & Chief Scientific Officer (Age 60, Pay $443.79k)
  • Mr. José E. Rivera, Exec. VP, Gen. Counsel & Company Sec. (Age 55, Pay $637.65k)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 48)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 35)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna, Founder & Member of Scientific Advisor Board (Age 57)
  • Dr. Derrick J. Rossi, Founder & Member of Scientific Advisor Board

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (8.64%), Nikko Asset Management Americas Inc. (8.64%), BlackRock Inc. (8.55%), Price T Rowe Associates Inc. MD (3.59%), Morgan Stanley (1.99%) and Dimensional Fund Advisors LP (1.67%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard, Jose E Rivera and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics
.

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., ExodusPoint Capital Management LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Engineers Gate Manager LP, and Squarepoint Ops LLC. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, John M Leonard, Jose E Rivera, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Federated Hermes Inc., Avidity Partners Management LP, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Jennison Associates LLC, Hitchwood Capital Management LP, and MPM Oncology Impact Management LP.
View insider buying and selling activity for Intellia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $60.46.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $3.57 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 270 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

Where are Intellia Therapeutics' headquarters?

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.